ARCH Venture Management, LLC reported 12 positions worth $1.10B for the quarter ended Jun 30, 2026, up 62.5% on the prior quarter. It opened 3 new positions, added to 0, trimmed 1 and exited 1. Its largest holding is Parabilis Medicines, Inc. at 16% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| QTTB Q32 Bio Inc. | -320.5K | $2.06M | 0.304% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | PBLS Parabilis Medicines, Inc. | Healthcare | 6.41M | $175.52M | 15.95% | +6.41M | – | New | 5.26% |
| 2 | BEAM Beam Therapeutics Inc. | Healthcare | 4.54M | $155.77M | 14.16% | 0 | 0.0% | Unchanged | 4.35% |
| 3 | RAPP Rapport Therapeutics, Inc. | Healthcare | 3.73M | $155.38M | 14.12% | 0 | 0.0% | Unchanged | 7.78% |
| 4 | SPTX Seaport Therapeutics, Inc. | Healthcare | 6.29M | $136.60M | 12.42% | +6.29M | – | New | 11.76% |
| 5 | ERAS Erasca, Inc. | Healthcare | 7.09M | $129.92M | 11.81% | 0 | 0.0% | Unchanged | 2.27% |
| 6 | VIR Vir Biotechnology, Inc. | Healthcare | 12.69M | $129.35M | 11.76% | -222.5K | -1.7% | Reduced | 7.5% |
| 7 | MAZE Maze Therapeutics, Inc. | Healthcare | 4.12M | $122.98M | 11.18% | 0 | 0.0% | Unchanged | 6.98% |
| 8 | LYEL Lyell Immunopharma, Inc. | Healthcare | 3.25M | $45.53M | 4.14% | 0 | 0.0% | Unchanged | 13.88% |
| 9 | GENB Generate Biomedicines, Inc. | Healthcare | 1.94M | $32.80M | 2.98% | 0 | 0.0% | Unchanged | 1.52% |
| 10 | TXG 10x Genomics, Inc. | Healthcare | 217.8K | $8.35M | 0.759% | 0 | 0.0% | Unchanged | 0.17% |
| 11 | BOLD Boundless Bio, Inc. | Healthcare | 2.69M | $6.74M | 0.612% | +2.69M | – | New | 11.99% |
| 12 | GOSS Gossamer Bio, Inc. | Healthcare | 100.7K | $1.33M | 0.121% | 0 | 0.0% | Unchanged | 1.65% |
Tip. Select a row to see that position’s full history at ARCH Venture Management.
As of its Q2 2026 13F filing, ARCH Venture Management, LLC’s five largest positions were Parabilis Medicines, Inc. (PBLS) at 16.0%, Beam Therapeutics Inc. (BEAM) at 14.2%, Rapport Therapeutics, Inc. (RAPP) at 14.1%, Seaport Therapeutics, Inc. (SPTX) at 12.4%, Erasca, Inc. (ERAS) at 11.8% of the reported portfolio.
ARCH Venture Management, LLC reported a 13F portfolio worth $1.10B across 12 positions for Q2 2026. That is up 62.5% from the previous quarter.
Its largest purchases by value were Parabilis Medicines, Inc. ($175.52M), Seaport Therapeutics, Inc. ($136.60M), Boundless Bio, Inc. ($6.74M). It opened 3 new positions.
Its largest sales by value were Vir Biotechnology, Inc. ($2.27M), Q32 Bio Inc. ($2.06M). It exited 1 positions entirely.
From the Form 13F-HR reports ARCH Venture Management, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.